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Summary
Recent efforts to develop pharmacologic agents that restore function to mutant forms of p53 hold significant promise in
cancer therapy. Here, we examine the effects of such pharmacologic activation of p53 function using a small molecule,
PRIMA-1, and a model system employing a p53 protein fused to a mutant steroid binding domain of the murine estrogen
receptor (p53ERtam) that renders it responsive only in the presence of 4-hydroxytamoxifen. In either case, p53 activation
triggered apoptosis that was not inhibited by the presence of macromolecular synthesis inhibitors. This p53-induced,
transcription-independent apoptosis is Bax dependent, proceeds in the absence of a nucleus, and involves Bax translocation
and cytochrome c release. Hence, pharmacologic p53 modulators can activate a transcription-independent apoptotic
program.
Introduction way is regulated by various pro- and antiapoptotic BCL-2 family
proteins, which govern the integrity of the mitochondrial mem-
branes (Green and Evan, 2002; Adams and Cory, 1998). Mito-The p53 tumor suppressor integrates cellular stresses, such as
growth factor or oxygen deprivation, DNA damage, and onco- chondrial outer membrane permeabilization (MOMP) results in
the liberation of apoptogenic factors, including cytochrome c,genic transformation, to trigger either cell cycle arrest and se-
nescence, DNA repair, or apoptosis (Vogelstein et al., 2000). SMAC/DIABLO, HtrA2/Omi, AIF, or EndoG, which facilitate cas-
pase activation or nuclear DNA fragmentation (Green, 2000).Thereby, p53 prevents the propagation of cells that have lost
their genetic or functional integrity and thus could threaten the Accordingly, p53 was shown to induce cytochrome c release
and caspase activation via proapoptotic BCL-2 proteins (Schu-organism by cancerous outgrowth. Accordingly, humans and
mice with germline defects of the TP53 gene are prone to early ler et al., 2000, 2003; Zhang et al., 2000), and fibroblasts from
mice deficient in BAX, APAF-1, or caspase-9 were resistant todevelopment of tumors (Malkin et al., 1990; Donehower et al.,
1992). Further, in murine models, the development of genetically p53-dependent cell death (McCurrach et al., 1997; Soengas et
al., 1999).programmed cancers is greatly accelerated on a p53-deficient
background (Eischen et al., 1999; Schmitt et al., 1999; Johnson It is thought that p53 signals apoptosis through its activity
as a sequence-specific transcriptional activator of target genes,et al., 2001; Van Dyke and Jacks, 2002), and the majority of
human cancers show mutations of TP53 or its regulators (Olivier such as BAX, NOXA, PUMA, BID, APAF-1, CD95, DR5, or
p53AIP1 (Miyashita and Reed, 1995; Wu et al., 1997; Mu¨ller etet al., 2003). In vivo dissection of p53-dependent tumor suppres-
sion revealed apoptosis as its main effector mechanism (Schmitt al., 1998; Oda et al., 2000a, 2000b; Yu et al., 2001; Nakano and
Vousden, 2001; Moroni et al., 2001; Sax et al., 2002). Accord-et al., 2002). Hence, tumor cell-specific induction of apoptosis
by pharmacologic activation of mutant p53 is an attractive thera- ingly, pharmacologic strategies to activate mutant p53 have
focused on the identification of compounds that restore its ca-peutic and preventive strategy in oncology. A better understand-
ing of the molecular events controlling p53-induced cell death pacity to bind specific DNA sequences (Wieczorek et al., 1996;
Selivanova et al., 1997; Foster et al., 1999; Bykov et al., 2002).is a prerequisite for such an approach.
Genetic and biochemical evidence suggests that p53 en- In addition to transactivation of target genes, evidence from
several experimental systems and laboratories has suggested agages apoptotic caspase activation mainly through the intrinsic,
“mitochondrial” pathway (Schuler and Green, 2001). This path- contribution of transcription-independent components to p53s
S I G N I F I C A N C E
The p53 tumor suppressor is encoded by the most commonly mutated gene in cancer, and its role in preventing oncogenesis through
the induction of apoptosis is well established. While most functions of p53 involve its activity as a transcription factor, evidence has
also implicated transcription-independent activities in its induction of apoptosis. Pharmacologic approaches to restore p53 function
have focused on the reestablishment of transcriptional activity, but here we show that such restoration triggers Bax-dependent
apoptosis involving cytochrome c release and caspase activation in the absence of transcription (or, indeed, a nucleus). Therefore,
approaches for the restoration of this transcription-independent proapoptotic activity of p53 are viable therapeutic strategies.
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Figure 1. p53-induced apoptosis in the absence of DNA binding, transcription, and translation is blocked by BCL-XL
A: Schematic representation of the p53 domains and mutants expressed in NCI-H1299 cells.
B: NCI-H1299 cells were transiently transfected with indicated p53 vectors and analyzed 48 hr after by Annexin V-FITC staining and FACS.
C: NCI-H1299 were transiently transfected with p53N1-102, treated with 10 nM actinomycin D or 10 g/ml cycloheximide (or vehicle), and analyzed 48 hr after
by Annexin V-FITC staining and FACS.
D: NCI-H1299 were transfected and treated as in C, but BCL-XL was added where indicated. Data are representative of three independent experiments.
Error bars equal  SD.
proapoptotic activity (Caelles et al., 1994; Wagner et al., 1994; marized in Figure 1A (Levine, 1997; Vogelstein et al., 2000). The
Haupt et al., 1995; Chen et al., 1996). Modulation of the localiza- integrity of the central DNA binding domain was shown to be
tion of death receptors, a requirement for caspase-8, as well essential for p53s function as a transcriptional activator, and
as a direct impact of p53 on mitochondria have been proposed the majority of p53 mutations found in cancer target this domain
as transcription-independent apoptotic mechanisms (Bennett (Olivier et al., 2003). Additional domains, such as the amino-
et al., 1998; Marchenko et al., 2000; Dumont et al., 2003; Mihara terminal proline-rich domain, were shown to be important for
et al., 2003; Ding et al., 2000). As the vast majority of naturally transrepression and induction of apoptosis (Walker and Levine,
occurring p53 mutations target the DNA binding domain and 1996; Sakamuro et al., 1997; Venot et al., 1999). Recently, it
thereby abolish its activity as a transcriptional activator, we was suggested that transcription-independent induction of apo-
reasoned whether activation of p53s transcription-independent ptosis by p53 also required the integrity of the DNA binding
proapoptotic activity might be a feasible therapeutic strategy. domain (Mihara et al., 2003). However, the same group pre-
To this end, we have established experimental systems to define viously reported that the core domain mutant p53R175H was still
and validate the p53 domain crucial for transcription-indepen- capable of inducing apoptosis when targeted to the mitochon-
dent apoptosis, as well as to dissect this activity at a molecular dria (Marchenko et al., 2000). In order to define minimal require-
level. We provide models for the “pharmacologic activation” of ments for p53-induced transcription-independent apoptosis,
p53 at the cellular and subcellular levels by the use of an induc-
we expressed various artificial p53 mutants (Figure 1A) in NCI-ible p53 fusion protein and a small molecular compound capable
H1299 lung cancer cells (Figure 1B) and Saos-2 osteosarcomaof activating wild-type or mutant p53, and in both cases, we
cells (not shown). These studies confirmed that a transactivationfind that apoptosis can be induced in a manner that is p53
domain mutant p53L22Q,W23S was still capable of inducing apopto-dependent but transcription independent.
sis (Haupt et al., 1995). Similarly, a p53NLS mutant with a de-
stroyed nuclear localization signal, which is targeted to the cyto-Results
plasm (not shown), induced apoptosis in this assay (Figure 1B).
In contrast, a p53PP mutant lacking the amino-terminal proline-The amino terminus of p53 including its proline-rich
rich regulatory domain (residues 62 to 91) (Walker and Levine,regulatory domain is necessary and sufficient
1996; Sakamuro et al., 1997) exhibited no proapoptotic activityto induce transcription-independent apoptosis
(Figure 1B). A p53N1-102 truncation mutant, which encompassesExtensive characterization has led to the definition of functional
domains of the p53 tumor suppressor protein, which are sum- the proline-rich domain but not the DNA binding and carboxy-
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Figure 2. Transcription-independent, p53ERtam-induced apoptosis occurs independently of de novo protein synthesis and CD95/Fas/APO-1 redistribution
A: The stable expression of p53ERtam and p53PPERtam in NCI-H1299 is equal to UV-induced expression of endogenous p53 in HCT116 cells. Both exogenous
and endogenous p53 were detected by Western blot analysis with anti-p53 clone Do7. Actin is shown as a loading control.
B: p53ERtam-induced gene expression in NCI-H1299 is inhibited by cycloheximide. Cells were cultured with indicated concentrations of cycloheximide (or
vehicle) for 60 min prior to treatment with 100 nM 4-OHT (or vehicle) for 24 hr before Western blot analysis with anti-p21WAF1/CIP1, Bax, and Bid. The blot was
not stripped of anti-Bax antibody before probing for Bid. Actin is shown as a loading control.
C: p53ERtam-induced apoptosis occurs without de novo protein synthesis and requires the p53 proline-rich domain (amino acids 62–91) in NCI-H1299 cells.
Cells were cultured with 10 g/ml cycloheximide (or vehicle) for 60 min prior to treatment with 100 nM 4-OHT (or vehicle) for 48 hr. Apoptosis was measured
by Annexin V-FITC staining and FACS.
D: CD95/Fas/APO-1 is not redistributed to the cell surface during p53ERtam-induced death. NCI-H1299 were cultured with 10 g/ml cycloheximide for 60
min prior to treatment with 100 nM 4-OHT. Cells were harvested at indicated time points, stained with anti-CD95/Fas/APO-1-FITC before FACS analysis.
Overlapping data points are 0 min, 30 min, 60 min, 120 min, 12 hr of 4-OHT treatment, and a CD95/Fas/APO-1 negative control. The FL1-positive peak is a
CD95/Fas/APO-1 overexpressing cell line positive control. Data are representative of several independent experiments. Error bars equal  SD.
terminal domains, still exhibited a profound and reproducible struct (Vater et al., 1996), which we stably expressed in cancer
cell populations at levels comparable to those of endogenousproapoptotic activity (Figure 1B). In order to exclude residual
effects of the p53N1-102 mutant on target gene induction, NCI- p53 following DNA damage (Figure 2A) or expression of onco-
genes (Supplemental Figure S1 at http://www.cancercell.org/H1299 cells transfected with this mutant were then additionally
treated after 24 hr with inhibitors of transcription and translation, cgi/content/full/4/5/371/DC1). Both the wild-type p53 and
p53PP cDNA were fused to the mutant ligand binding domainactinomycin D and cycloheximide (CHX) (Figure 1C). While this
treatment does not exclude gene expression effects during the of the murine estrogen receptor, which renders the resulting
fusion protein inactive potentially through complex formationexpression of the transfected mutant, it should have prevented
late events that might be rate limiting for apoptosis. We and with HSP90. Addition of the specific ligand 4-hydroxytamoxifen
(4-OHT) releases this complex, resulting in an active fusion pro-others have previously shown that p53-dependent apoptosis
mainly proceeds through the intrinsic, mitochondrial pathway, tein (Littlewood et al., 1995). This system was devised to model
pharmacologic modulation of p53 activity. 4-OHT treatment ofwhich is regulated by the BCL-2 family of proteins (Soengas et
al., 1999; Schuler et al., 2000, 2003). Accordingly, transcription- cells stably expressing p53ERtam (Figure 2B) as well as
p53PPERtam (data not shown) induced the p53 effector proteinsindependent apoptosis induced by p53N1-102 was effectively
blocked by antiapoptotic BCL-XL, either in the absence or pres- p21WAF1/CIP1, Bax, and Bid (El-Deiry et al., 1993; Harper et al.,
1993; Xiong et al., 1993; Miyashita and Reed, 1995); and thisence of actinomycin D or CHX (Figure 1D). In summary, the
amino terminus of p53 confers a proapoptotic activity, which effect was suppressed by pretreatment with CHX. In contrast,
activation of p53ERtam, but not p53PPERtam, induced apoptosisdepends on the proline-rich regulatory domain and which does
not require transactivation of target genes. in NCI-H1299 cells, and this was not inhibited by pretreatment
with CHX (Figure 2C). Comparable results were obtained inAs overexpression studies can be prone to nonspecific ef-
fects, we made use of a pharmacologically regulated p53 con- several additional cell lines, including Saos-2, Jurkat, Molt4,
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Figure 3. BAX is required for transcription-independent, p53-induced apoptosis
A and B: HCT116BAX/ and HCT116BAX/ were transiently transfected with p53ERtam or p53PPERtam, cultured with 5 g/ml cycloheximide (or vehicle) for
60 min, and treated with 100 nM 4-OHT (or vehicle) for 48 hr before Annexin V-FITC staining and FACS. Where indicated, a sublethal dose of BAX was
cotransfected. To determine the sublethal transfection dose of BAX, HCT116BAX/ were transiently transfected with increasing doses of BAX and Us9-GFP,
a marker for transfection efficiency, for 36 hr and analyzed by FACS for % transfected (GFP positive) and % apoptosis (Annexin V-PE). Western blot analysis
was performed to ensure appropriate BAX expression in the HCT116 cell lines before and after transfection. GAPDH is shown as a loading control. *
designates untransfected cells. Error bars equal  SD.
HCT116, and oncogene-expressing murine fibroblasts (Figure deficient (e.g., Trp53QS) and/or DBD mutant (e.g., p53I254D) forms
of p53 may lack cytoplasmic proapoptotic activity not only due3A and data not shown). Using a similar system and vascular
smooth muscle cells, Bennett et al. suggested redistribution to the loss of transcriptional activity, but also due to the altered
localization (Supplemental Figure S2 online); i.e., enhanced nu-of the CD95/Fas/APO-1 receptor as the mechanism of p53-
induced transcription-independent apoptosis (Bennett et al., clear accumulation that may result from the loss of MDM2 regu-
lation.1998). However, we failed to observe a detectable redistribution
of CD95/Fas/APO-1 following p53ERtam activation in our experi- Recently, we have shown that during p53-dependent apo-
ptosis, BAX translocates from the cytoplasm to mitochondria,mental system (Figure 2D).
Despite our results that transient expression of p53L22Q,W23S where it induces the release of apoptogenic factors including
cytochrome c (Schuler et al., 2003). These same events wereis competent to induce apoptosis (Figure 1B), an in vivo mouse
model of the equivalent murine mutant (Trp53QS) indicates that observed following 4-OHT activation of p53ERtam in the presence
of CHX (Supplemental Figure S3 on Cancer Cell website), dem-this p53 mutant is exclusively nuclear and does not shuttle
to the cytoplasm as wild-type p53 (Jimenez et al., 2000). We onstrating in our experimental system that p53-dependent apo-
ptosis in the absence of translation involves the activation ofconfirmed these results (Supplemental Figure S2 on Cancer
Cell website) and concluded that cytoplasmic effects of the the mitochondrial pathway of caspase activation. In summary,
pharmacologic activation of p53ERtam stably expressed at physi-endogenous p53 mutant would therefore not be observed in
our system. Furthermore, we speculate that transactivation- ological levels was sufficient to induce apoptosis in a transcrip-
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Figure 4. Pharmacological activation of p53 causes BAX translocation, cytochrome c release, and phosphatidylserine externalization in nuclei-free cytoplasts
A: p53ERtam-H1299 cells and cytoplasts were plated 5 hr before a 60 min pretreatment with 10 g/ml cycloheximide and 100 nM 4-OHT for 36 hr. Intact
cells and cytoplasts were then harvested, washed once with PBS, and stained with Annexin V-PE before FACS analysis.
B: Same methods as in A, except p53PPERtam -H1299 cytoplasts were also prepared and analyzed for apoptosis.
C: Cytoplasts were prepared, distinguished, and separated from intact cells by staining with acridine orange and FACS. The pure cytoplast population
(acridine orange negative) was cultured for 5 hr, pretreated with 10 g/ml cycloheximide for 60 min, and treated with 100 nM 4-OHT (or vehicle) for 36
hr. Cytoplasts were then harvested, and the mitochondrial and S-100 fractions were isolated. Western blot analysis comparing the localization of cytochrome
c and Bax was performed. VDAC is shown as a loading control for the mitochondrial pellet. (p) and (c) indicate mitochondrial pellet and cytosol,
respectively. Data are representative of two independent experiments.
tion-independent manner. Again, this proapoptotic activity of expressed the p53ERtam and p53PPERtam fusion proteins in
HCT116 colorectal cancer cells with heterozygous or homozy-p53 depended on the proline-rich regulatory domain.
gous deletions of the BAX gene (Zhang et al., 2000). While
4-OHT activation of p53ERtam but not p53PPERtam readily in-Transcription-independent apoptosis of cancer cells
duced apoptosis in BAX-proficient HCT116, loss of BAX com-by pharmacologically activated p53 requires
pletely protected HCT116 cells against p53-induced apoptosisproapoptotic BAX
in the absence or in the presence of the translation inhibitorThe MOMP to release apoptogenic factors, such as cytochrome
CHX (Figure 3A). Sensitivity toward p53-mediated apoptosisc, is regulated by the pro- and antiapoptotic BCL-2 family of
was restored by reexpression of sublethal levels of BAX in BAX-proteins (Green and Evan, 2002). Previously, we and others
deficient HCT116 cells (Figures 3A and 3B). Hence, transcrip-have shown that proapoptotic BAX is a crucial mediator of p53-
dependent apoptosis in cancer cell lines and murine fibroblasts tion-independent, p53-mediated apoptosis involves the activa-
tion of proapoptotic BCL-2 family proteins, such as BAX, to(McCurrach et al., 1997; Schuler et al., 2000, 2003; Zhang et al.,
2000). To study if BAX is required for transcription-independent induce MOMP (Saito et al., 2000; Wei et al., 2000; Kuwana et
al., 2002).induction of apoptosis in the present experimental system, we
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Pharmacologically activated p53 induces apoptosis
through the mitochondrial pathway
in nuclei-free cytoplasts
As we could not formally exclude the induction of an unidentified
proapoptotic p53 target protein in the presence of CHX, we set
out to study the apoptotic activity of p53ERtam in the absence
of nuclei, thus eliminating any possibility of p53-mediated trans-
activation or transrepression of genes. Previously, it has been
shown that apoptosis can proceed in enucleated cells (cy-
toplasts). Cytoplasts undergoing apoptosis display the same
features, such as caspase activation, phosphatidylserine expo-
sure, and cleavage of caspase substrates, that are observed
during apoptosis of intact cells (Jacobsen et al., 1994; Martin
et al., 1996). To this end, we prepared cytoplasts from cells
stably expressing physiological levels of the p53ERtam or the
p53PPERtam fusion proteins (Supplemental Figure S4 on Cancer Figure 5. Pharmacological activation of p53 causes cytochrome c release
in vitroCell website). When 4-OHT was added to NCI-H1299 cytoplasts
S-100 cytosol from p53ERtam-H1299 or p53PPERtam -H1299 was combined withexpressing p53ERtam, apoptotic membrane changes occurred
freshly isolated murine liver mitochondria in the presence of 100 nM 4-OHTat the same rate and extent as in intact cells (Figure 4A). More-
(or vehicle). Recombinant BCL-XLC (or PBS) was added where indicated.over, 4-OHT sensitized p53ERtam-expressing cytoplasts to staur- Western blot analysis comparing cytochrome c localization was performed.
osporine-induced apoptosis (Supplemental Figure S5A online). (p) and (c) indicate mitochondrial pellet and cytosol, respectively. Data
are representative of two independent experiments.The proapoptotic activity of p53 in cytoplasts also required the
proline-rich regulatory domain (Figure 4B and Supplemental
Figure S5A). As in intact cells (Supplemental Figure S3B), p53-
dependent apoptosis of cytoplasts proceeded via the mitochon-
previous observations in cells and cytosols prepared from cellsdrial pathway, as evidenced by BAX translocation, release of
overexpressing p53 (Schuler et al., 2000).mitochondrial cytochrome c (Figure 4C), and loss of the mito-
chondrial transmembrane potential m (Supplemental Figure The small drug PRIMA-1 activates mutant p53 to induceS5B) following 4-OHT activation of p53ERtam. The induction of
transcription-independent apoptosisapoptosis in nuclei-free cytoplasts unambiguously demon-
Our results in cytoplasts and in the cell-free system unambigu-strates a cytoplasmic proapoptotic activity of the p53 tumor
ously demonstrate that the p53 tumor suppressor protein cansuppressor protein, which depends on its amino-terminal pro-
elicit a proapoptotic activity that does not depend on an intact
line-rich regulatory domain.
DNA binding domain, but on the amino-terminal proline-rich
domain. Recently, several small molecular compounds were
Pharmacologically activated p53 induces rapid identified that allow pharmacologic inhibition (Komarov et al.,
cytochrome c release from isolated mitochondria 1999) of wild-type p53 or activation of mutant p53 (Selivanova
in a cell-free reconstituted system et al., 1997; Foster et al., 1999; Bykov et al., 2002). The latter
Previously, it has been shown that p53 could directly impact compounds were thought to achieve tumor suppression by
on mitochondria to induce transcription-independent apoptosis. modulating the capacity of mutant p53 to bind DNA and thereby
A mtHsp70/Grp75-dependent import of p53 into mitochondria restoring its activity as a transactivator (Wieczorek et al., 1996;
(Marchenko et al., 2000; Dumont et al., 2003), as well as complex Selivanova et al., 1997; Foster et al., 1999; Bykov et al., 2002).
formation of p53 with antiapoptotic BCL-2 and BCL-XL (Mihara In light of our present observations, it appears possible that
et al., 2003), were suggested as transcription-independent pro- compounds modulating the conformation and activation status
apoptotic mechanisms. To further study the potential impact of of p53 DNA binding domain (DBD) mutants could also activate
pharmacologically activated p53 on mitochondria, we devel- p53 transcription-independent proapoptotic activity.
oped a cell-free system using cytosolic extracts prepared from Therefore, we studied the influence of the small drug
cell populations stably expressing physiological levels of the PRIMA-1 (Bykov et al., 2002) in our experimental system of
p53ERtam or p53PPERtam fusion proteins. These cytosolic ex- p53-induced, transcription-independent apoptosis in a panel of
tracts were incubated with freshly isolated murine liver mito- human non-small cell lung carcinoma cell lines with defined
chondria in the presence or absence of 4-OHT. Only p53ERtam, p53 status. The cell lines NCI-H460, NCI-H23, and NCI-H1299
and not p53PPERtam, could be activated by 4-OHT to induce (p53wild-type, p53M246I, and p53/, respectively) were cultured in
cytochrome c release from isolated mitochondria (Figure 5). 20g/ml CHX for 30 min prior to treatment with 40M PRIMA-1.
Cytochrome c release was inhibited by the addition of recombi- PRIMA-1 induced rapid apoptosis in cells expressing either
nant BCL-XL, which again supports the regulation of this pro- p53wild-type or p53M246I regardless of protein synthesis (Figure 6A),
cess by the BCL-2 family of proteins (Figure 5). Moreover, the while no effect of PRIMA-1 was observed in the p53/ cells.
p53-induced release of cytochrome c proceeded independently Furthermore, the induction of apoptosis by PRIMA-1 proceeds
of caspase activity, as the addition of zVAD-fmk had no effect through a caspase-dependent pathway, as inhibition of caspase
(Supplemental Figure S6 on Cancer Cell website), suggesting activity by zVAD-fmk completely abrogated death.
that p53 acts upstream of mitochondria to regulate BCL-2 pro- To rule out occult transcription/translation during PRIMA-1-
induced death, cytoplasts were prepared from NCI-H1299 cellsteins and mitochondrial function. This is consistent with our
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Figure 6. Activation of p53 by PRIMA-1 induces
apoptosis in the absence of de novo protein ex-
pression or a nucleus
A: NCI-H460, NCI-H23, and NCI-H1299 (p53wt,
p53M246I, p53/, respectively) human non-small
cell lung carcinoma cells lines were pretreated
with 20 g/ml cycloheximide for 30 min prior to
treatment with 40 M PRIMA-1 (or DMSO). Where
indicated, 100 M zVAD-fmk (or DMSO) was
added as indicated. Cells were harvested 24 hr
after treatment and stained with Annexin V-FITC
before FACS analysis. Error bars equal  SD.
B: Cytoplasts were prepared from empty vector,
p53R273H or p53PP transfected NCI-H1299 cells.
After preparation, the cytoplasts were cultured
for 8 hr, pretreated with 10 g/ml cycloheximide
and/or 100 M zVAD-fmk for 60 min, and 2 M
PRIMA-1 for 36 hr. DMSO was added as vehicle
for PRIMA-1 and zVAD-fmk. Cytoplasts were har-
vested and stained with Annexin V-FITC before
FACS analysis. Data are representative of two
independent experiments. Error bars equal SD.
Equal expression of p53R273H and p53PP in cyto-
plasts was confirmed by immunoblotting (inset).
equally expressing the DBD mutant p53R273H or the p53PP mutant that restore the DNA binding activity of mutant p53 (Selivanova
et al., 1997; Foster et al., 1999; Bykov et al., 2002). These(Figure 6B inset) and were treated with PRIMA-1 in the absence
or presence of CHX. Interestingly, PRIMA-1 clearly induced apo- approaches have in common that they rely on the preserved
capacity of the target cell to respond with transcriptional activa-ptosis in cytoplasts expressing p53R273H, while p53PP and control
cytoplasts proved resistant (Figure 6B). PRIMA-1-induced apo- tion of tumor-suppressive target genes. Most likely all cancer
cells cannot fulfil this prerequisite. In order to bypass this poten-ptosis of p53R273H cytoplasts was blocked by pretreatment with
the caspase inhibitor zVAD-fmk, but not by CHX (Figure 6B). tial limitation but still make use of the unique strategic role of p53
in tumor suppression, we set out to study possible transcription-This ensured that induction of apoptosis by the combination of
PRIMA-1 and p53R273H did not involve the translation of residual independent, tumor-suppressive activities of the p53 protein.
The induction of apoptosis seems to be the main tumor sup-RNA, which might still be present in cytoplasts, and that this
process requires caspase activity. The lack of PRIMA-1-induced pressive activity of p53 in vivo (Schmitt et al., 2002). In general,
the execution of apoptosis does not require transcription of newapoptosis in p53PP-expressing cytoplasts supports the speci-
ficity of this activity in our system. genes and, in fact, can be triggered to proceed in nuclei-free
cytoplasts (Jacobsen et al., 1994; Schulze-Osthoff et al., 1994;
Martin et al., 1996). These observations prompted us to exploreDiscussion
the therapeutic modulation of p53s capacity to induce apopto-
sis in the absence of transcription.Deregulation of the p53 tumor suppressor pathway is the most
prevalent genetic aberration observed in cancer (Sherr and The engagement of the apoptotic machinery by p53 has
been studied using a variety of approaches, which have pro-McCormick, 2002). Accordingly, functional restoration of this
pathway is an attractive “universal” therapeutic and preventive vided conflicting results regarding the requirement of the intact
p53 DNA binding domain or transactivation domain for the pro-strategy in oncology. So far, efforts have focused on somatic
gene transfer approaches (Roth et al., 1996; Schuler et al., 1998, apoptotic activity of the molecule (Haupt et al., 1995; Chen et
al., 1996; Attardi et al., 1996; Zhu et al., 2000; Chao et al., 2000).2002; Kuball et al., 2002) and the identification of compounds
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Studies using a temperature-sensitive p53 mutant also revealed supports further testing of the applicability of transcription-inde-
contradictory results in different cell lines (Caelles et al., 1994; pendent p53 activation in vivo.
Sabbatini et al., 1995). All studies failed to provide a mechanism The transcription-independent p53-mediated apoptosis
for the potential transcription-independent proapoptotic activity seems to be executed by a pathway similar to the one activated
of p53. Recently, it has been established that p53-dependent under conditions allowing transcription (Schuler and Green,
apoptosis mainly proceeds via the intrinsic, mitochondrial path- 2001). The release of cytochrome c from isolated mitochondria
way of caspase activation (Schuler and Green, 2001). Intriguing proceeds through a caspase-independent mechanism (Supple-
studies by Moll et al. suggest that p53 might directly impact on mental Figure S6 on Cancer Cell website), whereas the execution
the mitochondria. First, it was reported that p53 is imported phase of apoptosis (i.e., nuclear fragmentation and phosphati-
into the mitochondria through a mtHsp70/Grp75-dependent dylserine externalization, Figure 6) requires caspase activity, impli-
mechanism (Marchenko et al., 2000). Moreover, the mitochon- cating mitochondria as the central mediators of p53-induced
drial localization of p53 was found to be regulated by the amino- apoptosis. The requirement of BAX and the inhibition by BCL-
terminal polymorphism R72P, which also impacts on the interac- XL in our system points to an involvement of the BCL-2 family
tion between p53 and its negative regulator MDM2 (Dumont et of proteins. The activation of BAX-type proteins through p53
al., 2003). In the latter study, inhibitors of nuclear export of p53 may proceed by displacing them from binding antiapoptotic
were shown to prevent apoptosis, thus arguing for an important BCL-2-type proteins, as suggested (Mihara et al., 2003). Alterna-
contribution of extranuclear p53 to the induction of cell death tively, p53 could directly activate BAX-type proteins through its
(Dumont et al., 2003). Exactly how mitochondrial p53 would proline-rich domain in a way analogous to BH3-only members
trigger apoptosis remains unclear. It has been proposed that of the BCL-2 family (Huang and Strasser, 2001) or peptides
p53 can engage a novel caspase-8-dependent pathway to in- derived from the BH3 domain of BID (Letai et al., 2002). The
duce apoptosis in the absence of transcription (Ding et al., development of a cell-free system of p53-dependent apoptosis
2000). More recently, a direct physical interaction of p53 with now enables the systematic study of factors contributing to the
antiapoptotic BCL-2 and BCL-XL through its DNA binding do- process of BAX activation by p53.
main was demonstrated by coimmunoprecipitation and pull- Despite the conclusive evidence presented here, it remains
down experiments (Mihara et al., 2003). In this model, mitochon- open why expression of most p53 DNA binding domain mutants
drial p53 would bind antiapoptotic BCL-2 proteins, thereby fails to induce apoptosis despite the presence of an intact pro-
liberating proapoptotic proteins such as BAX or BAK to induce line-rich domain. The answer to this most likely lies in the com-
MOMP and apoptosis, although this has not been demon- plex regulation of the p53 protein in vivo. It was shown that
strated. Residues 239 to 248 of the p53 DNA binding domain under apoptotic conditions, mitochondrially localized p53 is ubi-
plus flanking regions were apparently required for this interac-
quitinated (Dumont et al., 2003). Polyubiquitination of p53 in
tion. This model conveniently explains why hot spot mutations
general is mediated by MDM2, a transcriptional target of p53
of the p53 DNA binding domain not only abrogate transactiva-
acting in a regulatory negative feedback loop (Oren, 1999).
tion but also transcription-independent induction of apoptosis
Hence, nuclear export and thus mitochondrial translocation ofby p53 (Mihara et al., 2003). However, expression of DNA bind-
endogenous p53 might only be possible if the transcription-ing domain mutants, such as p53R175H, retargeted to the mito-
dependent p53-MDM2 regulation is maintained (Boyd et al.,chondria were still able to induce apoptosis (Marchenko et al.,
2000; Geyer et al., 2000). This would explain why DNA binding2000). In addition, p53 DNA binding domain mutants have been
domain mutants abolish both transcription-dependent and tran-described that locate to the cytoplasm but still induce apoptosis
scription-independent proapoptotic activities of p53. In additionupon transient expression (Crook et al., 1998).
to ubiquitination, nuclear p53 undergoes a plethora of posttrans-Our present study reveals that the amino-terminal proline-
lational modifications during the cellular stress response (Loh-rich regulatory domain (amino acids 62 to 91) is required for the
rum and Vousden, 1999), which impact on the conformationtranscription-independent proapoptotic activity of p53, whereas
and activity of the molecule. Does this put a question mark onthe DNA binding domain may be dispensable. The necessity
the therapeutic strategy to pharmacologically activate mutantof the proline-rich domain for tumor-suppressive and death-
p53 to induce transcription-independent apoptosis? The an-promoting functions of p53 has previously been highlighted,
swer most likely is no, as it was shown that mutant p53 notalthough a nuclear function for this domain was suggested
only accumulates in the nucleus, but is also found at the mito-(Walker and Levine, 1996; Sakamuro et al., 1997; Venot et al.,
chondria (Mihara et al., 2003). Pharmacologic modulation of the1999). Although mutations in this region are not common (Sun
active conformation of p53 seems achievable in vitro and inet al., 1996), several missense mutations have been identified in
vivo (Selivanova et al., 1997; Foster et al., 1999; Bykov et al.,a variety of human tumors (Database of germline p53 mutations:
2002). Based on the present study, more detailed functionalhttp://www.lf2.cuni.cz/projects/germline_mut_p53.htm). Using
analyses of p53s transcription-independent proapoptotic activ-a p53 fusion protein that can be pharmacologically activated,
ity can be performed. This will enable novel screening strategieswe now provide evidence in nuclei-free cytoplasts as well as in
for the identification of new p53 modifiers for prevention anda novel cell-free system that p53 in fact can induce apoptosis
treatment of cancer.through its proline-rich domain in the absence of transcription.
These systems provide a “proof-of-concept” for a therapeutic
Experimental proceduresstrategy employing pharmacologic modulation of p53s tran-
scription-independent apoptotic activity. Interestingly, a small Plasmids and vectors
molecular compound that was found to restore the DNA binding The plasmids pBabePuro.p53PPERtam and pcDNA3.1.p53N1-102 were obtained
conformation of mutant p53 (Bykov et al., 2002) also triggered by cloning the PCR-generated cDNA into the respective vectors. All inserts
were confirmed by sequencing. The plasmid pBabePuro.p53ERtam was pro-p53-dependent, transcription-independent apoptosis. This
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vided by T. Littlewood; various p53 mutants were gifts from A. Levine and was removed. Pellets were resuspended in 3 volumes of HB (10 mM HEPES,
pH 7.5, 5 mM MgCl2, 0.67 mM dithiothreitol, 0.67 mM phenylmethylsulfonylG. Wahl.
fluoride, and 50 ug/ml each leupeptin, aprotinin, and antipain) and incubated
on ice for 20 min. Suspensions were lysed through a 25 gauge needle,Cell culture
centrifuged twice at 12,500  g for 20 min at 4	C, and recentrifuged atNCI-H1299, NCI-H460, NCI-H23 (human non-small cell lung carcinoma),
100,000  g for 60 min at 4	C. Extracts were then clarified through a 0.2Saos-2 (human osteosarcoma), Molt4 (human acute lymphoblastic leuke-
m filter and brought to 5% glycerol. Freshly isolated murine liver mitochon-mia), and mouse embryonic fibroblasts were cultured in Dulbecco’s Modified
dria were isolated with mitochondria isolation buffer as described (FinucaneEssential Medium supplemented with 10% dextran/charcoal-treated fetal
et al., 1999; Schuler et al., 2000). For 6xHis-BCL-XL purification, BL-21 cellsbovine serum (dcFBS), L-glutamine, penicillin, and streptomycin (100 M
were grown in 2YT medium to OD400 
 0.6, induced with 0.4 mM IPTG for2-mercaptoethanol was added for Trp53QS MEF). Jurkat (human acute T cell
3 hr, and lysates were allowed to bind Ni2 agarose for 2 hr at 4	C. Theleukemia), L1210 (mouse lymphoma), and HCT116 (human colon carcinoma)
agarose beads were then washed thrice with PBS, washed twice with PBSwere cultured as above except with RPMI and McCoy’s 5a base media,
10 mM imidazol, and eluted with 500 mM imidazol overnight at 4	C beforerespectively. Stable cell lines were generated by retroviral infection with
dialysis in PBS. 200 g of extract was combined with 100 g mitochondria,pBabePuro.p53ERtam, pBabePuro.p53PPERtam, or pBabePuro-expressing vi-
100 nM 4-OHT (or ethanol), 1 g BCL-XL (or PBS) for 60 min (or as indicated)rions produced by a standard calcium phosphate DNA coprecipitation trans-
at 37	C. When indicated, the broad-spectrum caspase inhibitor benzyloxy-fection method with the Phoenix packaging line (a gift from G. Nolan). Puro-
carbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk, Enzyme Systemmycin-resistant clones were isolated and pools of 10 clones were used
Products) dissolved in DMSO was added at 10 M at the start of the incuba-for each analysis. All transient transfections were performed using Lipofec-
tion. Samples were centrifuged at 14,000  g for 20 min and cytosol andtamine 2000 as indicated by the manufacturer.
mitochondrial (washed twice with MIB) fractions were combined with SDS
loading buffer before SDS-PAGE and immunoblotting.Flow cytometry, microscopy, and apoptosis assays
Floating and adherent cells were harvested, washed, and stained with
Acknowledgmentsannexin V-FITC (BD Clontech) plus propidium iodide (PI) or by annexin V-PE,
and the percentage of apoptotic cells was measured by flow cytometry on
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Published: November 24, 2003Cells were trypsinized, incubated with 21 M cytochalasin B for 1 hr at
37	C, layered over a discontinuous Ficoll gradient (12.5%/15%/16%/17%/
References25% in 10% dcFBS/HBSS), and ultracentrifuged for 1 hr at 80,000  g at
37	C. Cytoplasts (12.5%/15% interface) and nucleoplasts (16%/17% inter-
face) were washed with 10% dcFBS/DMEM and plated before Hoechst Adams, J.M., and Cory, S. (1998). The Bcl-2 protein family: Arbiters of cell
survival. Science 281, 1322–1326.33342 staining. Propidium iodide staining after mild digitonin permeabiliza-
tion (20 g/ml in PBS, 10 min on ice) was used to distinguish cytoplasts
Attardi, L.D., Lowe, S.W., Brugarolas, J., and Jacks, T. (1996). Transcriptional
from intact cells. Cytoplast preparations were used only when enucleation activation by p53, but not induction of the p21 gene, is essential for onco-
was 50%. For FACS sorting of cytoplasts, enucleated/intact cells popula- gene-mediated apoptosis. EMBO J. 15, 3693–3701.
tions were stained with acridine orange (800 g/ml in complete media, 37	C
Bennett, M., MacDonald, K., Chan, S.-W., Luzio, J.P., Simari, R., and Weiss-for 30 min) before sorting using FACSDiva.
berg, P. (1998). Cell surface trafficking of Fas: A rapid mechanism of p53-
mediated apoptosis. Science 282, 290–293.Immunoblotting
Cytosolic extracts were prepared as previously described (Bossy-Wetzel Bossy-Wetzel, E., and Green, D.R. (1999). Caspases induce cytochrome c
and Green, 1999; Schuler et al., 2000). In brief, cells were harvested and release from mitochondria by activating cytosolic factors. J. Biol. Chem.
were incubated in a buffer containing 220 mM mannitol and 60 mM sucrose 274, 17484–17490.
on ice for 30 min. Then, cells were broken in a glass dounce homogenizer.
Boyd, S.D., Tsai, K.Y., and Jacks, T. (2000). An intact HDM2 RING-fingerThe homogenates were centrifuged at 18,000  g for 15 min, and the
domain is required for nuclear export of p53. Nat. Cell Biol. 2, 563–568.mitochondria-free supernatants were analyzed. Extracts of the pellets as well
as whole-cell extracts were obtained by dissolving in lysis buffer, followed by Bykov, V.J.N., Issaeva, N., Shilov, A., Multcrantz, M., Pugacheva, E., Chuma-
repetitive vortexing and freeze-thawing. After centrifugation at 18,000  g, kov, P., Bergman, J., Wiman, K.G., and Selivanova, G. (2002). Restoration
of the tumor suppressor function to mutant p53 by a low-molecular-weightthe resulting supernatants were analyzed. Cellular fractionation (Supplemen-
compound. Nat. Med. 8, 282–288.tal Figure S2 on Cancer Cell website) was performed as described (Nikolaev
et al., 2003). For SDS-PAGE, 25 or 50 g of total protein per lane were Caelles, C., Heimberg, A., and Karin, M. (1994). p53-dependent apoptosis
loaded on 6% or 15% gels. Primary antibodies were anti-p53 Do7, PAb122 in the absence of transcriptional activation of p53-target genes. Nature 370,
and PAb240, anti-p21/WAF1/CIP1 (clone SX118), anti-Bax (polyclonal rabbit 220–223.
antiserum), anti-cytochrome c (clone 7H8.2C12, all BD Pharmingen), anti-
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p53 transcriptional activity is essential for p53-dependent apoptosis follow-polyclonal anti-serum), and anti-actin (clone C4, ICN Pharmaceuticals).
ing DNA damage. EMBO J. 19, 4967–4975.
In vitro cytochrome c release assay Chen, X., Ko, L.J., Jayaraman, L., and Prives, C. (1996). p53 levels, functional
NCI-H1299 or Saos-2 cells expressing ERtam fusion proteins were harvested domains, and DNA damage determine the extent of the apoptotic response
of tumor cells. Genes Dev. 10, 2438–2451.by trypsinization, washed four times with ice-cold PBS, and all residual PBS
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